Physiology and Pharmacology of Spasticity
Spasticity is a movement disorder characterized by positive symptoms of abnormally excessive motor unit activity (dystonia, inappropriate co-contraction of antagonistic muscle groups, and hyperactive stretch reflexes and cutaneous flexor reflexes including a Babinski sign). Spasticity must be differentiated from the negative symptoms, i.e., a lack of normal motor function, which always accompany it. The negative symptoms, which include weakness or paralysis, unusual fatiguability, and lack of dexterity, are referred to in this chapter as “paresis.” Together, these two major consequences of damage to the central nervous system (CNS) characterize a syndrome known as “spastic paresis” (1).
KeywordsNegative Symptom Presynaptic Inhibition Reciprocal Inhibition Stretch Reflex Recurrent Inhibition
Unable to display preview. Download preview PDF.
- 1.Young, R. R. (1995) Spastic paresis, in Diagnosis and Management of Disorders of the Spinal Cord ( Young, R. R. and Woolsey, R. M., eds.), W.B. Saunders, Philadelphia, pp. 363–376.Google Scholar
- 2.Sindou, M. (1992) Microsurgical DREZ-tomy for the treatment of pain and spasticity, in Principles and Practice of Restorative Neurology ( Young, R. R. and Delwaide, P. J., eds.), Butterworth-Heinemann, Oxford, pp. 144–151.Google Scholar
- 3.Russell, W. R. and Young, R. R. (1969) Missile wounds of the parasagittal rolandic area, in Modern Neurology ( Locke, S., ed.), Little Brown, Boston, pp. 289–302.Google Scholar
- 5.Walsh, E. G. (1992) Muscles, Masses & Motion. Mac Keith Press, London, pp. 83–90, 154.Google Scholar
- 6.Rymer, W. Z. and Katz, R. T. (1994) Mechanisms of spastic hypertonia. Phys. Med. Rehab. 8, 441–454.Google Scholar
- 9.Hochman, S. and McCrea, D. A. (1987) The effect of chronic spinal transection on homonymous la EPSP rise times in triceps surae motoneurons in the cat. Abstr. Soc. Neurosci. 12, 186.Google Scholar
- 11.Delwaide, P. J. and Olivier, E. (1987) Pathophysiological aspects of spasticity in man, in Motor Disturbances ( Benecke, R., Conrad, B., and Marsden, C. D., eds.), Academic Press, London, pp. 153–167.Google Scholar
- 12.McLellan, D. L., Hassan, N., and Hodgson, J. A. (1985) Tracking tasks in the assessment of spasticity, in Clinical Neurophysiology in Spasticity ( Delwaide, P. J. and Young, R. R., eds.), Elsevier, Amsterdam, pp. 131–139.Google Scholar
- 17.Ward, A., Chaffman, M. O., and Sorkin, E. M. (1986) Dantrolene. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in malignant hyperthermia, the neuroleptic malignant syndrome and an update of its use in muscle spasticity. Drugs 32, 130–168.PubMedCrossRefGoogle Scholar
- 18.Gracies, J.-M. and Simpson, D. (1999) Neuromuscular blockers, in Rehabilitation Pharmacotherapy ( Nance, R W., ed.), W.B. Saunders, Philadelphia, pp. 357–383.Google Scholar
- 19.Nance, P. W. and Young, R. R. (1999) Antispasticity medications, in Rehabilitation Pharmacotherapy ( Nance, R W., ed.), W.B. Saunders, Philadelphia, pp. 337–355.Google Scholar
- 21.Bauer, H. J. and Hanefeld, F. A. (1993) Multiple Sclerosis. W.B. Saunders, Philadelphia, pp. 146–149.Google Scholar